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ABSTRACT: Hepatic fat export occurs by apolipoprotein B-100-containing
lipoprotein production, whereas impaired production leads to liver steatosis.
Hepatitis C virus (HCV) infection is associated to dysregulation of apoB-100
secretion and steatosis; however, the molecular mechanism by which HCV
affects the apoB-100 secretion is not understood. Here, combining quantitative
proteomics and computational biology, we propose ferritin heavy chain (Fth)
as being the cellular determinant of apoB-100 production inhibition. By means
of molecular analyses, we found that HCV nonstructural proteins and NS5A
appear to be sufficient for inducing Fth up-regulation. Fth in turn was found to
inhibit apoB-100 secretion leading to increased intracellular degradation via
proteasome. Notably, intracellular Fth down-regulation by siRNA restores
apoB-100 secretion. The inverse correlation between ferritin and plasma apoB-
100 concentrations was also found in JFH-1 HCV cell culture systems
(HCVcc) and HCV-infected patients. Finally, Fth expression was found to be required for robust HCV infection. These
observations provide a further molecular explanation for the onset of liver steatosis and allow for hypothesizing on new
therapeutic and antiviral strategies.
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■ INTRODUCTION
Hepatitis C virus (HCV)-associated morbidity and mortality
are mainly attributable to disease progression toward cirrhosis
and, consequently, hepatocellular carcinoma.1 In particular, the
alterations of lipid metabolism associated with HCV-chronic
infection, mainly hypobetalipoproteinemia (HBL) and hepatic
steatosis, are considered key risk factors in disease pro-
gression.2,3 HBL is a group of metabolic disorders characterized
by low levels of circulating apoB-100-containing lipoprotein
particles (VLDL and LDL). In particular, reduced production
of VLDL determines hepatic fat accumulation, often resulting
in steatosis.4 HBL is mainly caused by the impaired secretion of
apolipoprotein B-100 (apoB-100), the main constituent of
these lipoproteins.5 In fact, the VLDL secreted levels are
directly correlated to the balance between apoB-100 synthesis
and degradation processes.
VLDL synthesis occurs in two different stages: assembly and
intracellular maturation.6 In the first step, microsomal
triglyceride transfer protein (MTP), an endoplasmatic retic-
ulum (ER)-resident enzyme, promotes the addition of small
amounts of triglycerides (TGs) to apoB-100, while it
translocates across the ER membranes.7,8 In the second step,
VLDL precursors are fused with TG-rich droplets to form
mature and secretion-competent VLDL particles.
In genetic forms of HBL, mutations of the MTP gene lead to
the production of an abnormally short enzyme with reduced or
absent activity that generates poorly lipidated apoB-100.9 In the
absence of sufficient lipids, apoB-100 is unable to form mature
VLDL particles and is targeted to both co- and post-
translationally proteasome-dependent degradation.10 Similarly,
nonsense, frame-shift and splicing mutations of the apoB-100
gene generate truncated forms of the protein that are
cotranslationally ubiquitinated and degradated, thus leading to
HBL.11
While the rationale of several HBL genetic forms has been
clarified, the molecular mechanism responsible for the HCV-
associated low plasma apoB-100 concentration is yet unknown.
Although experimental models (i.e., subgenomic replicon
harboring hepatoma cell lines) allowed for pinpointing a causal
correlation between expression of the sole HCV nonstructural
(NS) proteins and the drastic inhibition of apoB-100 secretion,12
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the basis of the viral-induced inhibition of apoB-100 secretion
remains largely unknown.
The present study aimed to address this issue. By combining
stable isotope labeling with amino acids in cell culture
(SILAC)-based proteomic approach, computational interpreta-
tion of data set and molecular analysis we demonstrated that:
(i) the expression of HCV nonstructural proteins, and NS5A
appears to be sufficient, directly correlates with ferritin heavy
chain (Fth) up-regulation; (ii) HCV-induced Fth up-regulation
results in inhibition of apoB-100 secretion and in its increased
proteasome-associated degradation; (iii) Fth down-regulation
abolishes HCV-mediated apoB-100 secretion inhibition.
Notably, in a natural infection system (JFH-1 HCVcc), Fth is
required to sustain viral infection. Moreover, studies in HCV-
infected patients showed that circulating apoB-100 levels were
lower in donors with high ferritin values than in those with
normal ferritin concentrations.
■ EXPERIMENTAL SECTION
Ethics Statement
The study has been approved by the ethics committee of the
INMI “L. Spallanzani” IRCCS, Rome, Italy. This study is
included in the INMI “L. Spallanzani” IRCCS research program
entitled “Programma di ricerca corrente 2008”.
Analysis on human serum has been carried out on clinical
residual samples and analyzed anonymously. To protect patient
confidentiality, all patient identifiers were removed from the
samples to make them completely anonymous.
Reagents
The chemicals, reagents and suppliers that were used are listed
below: N,N,N′,N′-tetrametiletilenediammine (TEMED), So-
dium Dodecyl Sulfate (SDS), Tween 20, Albumin Serum
Bovine (BSA), Nonidet-p40, Phosphate Buffered Saline (PBS),
Dulbecco’s modified eagle medium (DMEM), Dulbecco’s
modified eagle medium nutrient mixture F-12 ham (DMEM
F-12), Trypsin-EDTA solution, Fetal Bovine Serum (FBS),
L-Glutamine, penicillin/streptomycin, trifluoroacetic acid, inter-
feron-alpha (IFN-α), Ponceau S solution, α-cyano-4-hydrox-
ycinnamic acid (CHCA), paraformaldehyde, Triton X-100,
donkey serum, oligonucleotides siCTR/siFTH-1, sodium
chloride (NaCl), EDTA, protease inhibitor cocktail (PIC),
dl-dithiothreitol (DTT), iodoacetamide (IAA), MG-132, N-acetyl
cysteine (NAC) and ammonium bicarbonate (NH4HCO3)
were purchased from Sigma-Aldrich (St. Louis, MO).
Acrylamide, Tris-HCl Buffer, Tris-glycine-SDS buffer, Bradford
Bio-Rad Protein Assay, Sypro Ruby gel stain, Precision Plus
Protein Standard were purchased from BioRad Laboratories
(Hercules, CA). Blasticidin and sucrose were purchased from
ICN Biomedical (Costa Mesa, CA). NuPAGE gel electro-
phoresis reagents, lipofectamine RNAiMAX reagent, SILAC
media DMEM-Flex, TRIzol reagent and 5−6-chloromethyl-2′,
7′dichlorodihydrofluorescein diacetate (CM-H2DCFDA) were
obtained from Invitrogen (Carlsbad, CA). Nytrocellulose
membranes (Protran BA85) were obtained from Whatman-
Schleicher & Schuel (Dassel, Germany). ECL Plus Western
Blotting Detection System was purchased from GE Healthcare
(Chalfont St Giles, U.K.). Methanol and acetonitrile (ACN)
were purchased from J.T. Baker (Phillipsburg, NJ). Vivaspin
15R ultracentrifuge columns were purchased from Sartorius
Stedim Biotech (Germany) and microcolumns ZipTip (μ-C18)
were purchased from Millipore Corporation (Ballerica, USA).
Anti-Calnexin, MTP, NS5A, and Albumin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, USA);
anti-Calreticulin and ERP57 antibodies were obtained from
Stressgen Biotechnologies (San Diego, CA). Anti-Apolipopro-
teinB-100 antibody was purchased from BD Biosciences (San
Jose, CA); anti-Ferritin heavy chain antibody was obtained
from AbCam (Cambridge, U.K.). Anti-GAPDH antibody was
purchased from Calbiochem Merck (Gibbstown, NJ) and anti-
Golgin97 antibody was obtained from Invitrogen (Carlsbad,
CA). Anti-Core antibody was purchased from Anogen
(Mississauga, Canada). Secondary antibodies were purchased
from Jackson Immunoresearch Laboratories (Baltimore, MD).
Cell Culture
All cells were maintained in a monolayer at 37 °C in 5% CO2.
For the proteasome inhibition assay, RepBlast and Huh7 cells
were incubated in DMEM F-12 for 3 h in the presence of MG-
132 10 μM. Cells were then lysed on ice with RIPA lysis buffer
(50 mM Tris HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 5 mM
EGTA, 1% Nonidet NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) containing freshly added protease
inhibitors and 1 mM PMSF. Cellular medium was collected,
centrifuged (17000× g, 4 °C, 10 min) to remove cells and
debris, and secreted proteins were concentrated into ultra-
filtration columns. Samples were analyzed by Bradford assay to
determine the protein concentration, then dissolved in SDS-
loading buffer and analyzed by Western blotting. For IFNα
treatment, 2 × 105 RepBlast and Huh7 plated in 6-cm dishes
were incubated in DMEM and then treated with IFNα 1000 U/mL.
The media was changed every 24 h for 4 days.
For HCVcc production, Huh7.5.1 cells were infected with
JFH-1-derived virus (MOI = 0.1) 2 days before plating. After 3
days of cultivation, the cells were lysed and culture media were
collected as previously described.
Membrane Floatation Assay
Gradients were formed by equal-volume (1,5 mL) steps of 20,
30, 40, 50, and 60% sucrose solutions in TNE buffer (10 mM
Tris-HCl, pH 8, 150 mM NaCl, 2 mM EDTA). Eight-hundred
micrograms of sample (1.5 mL) were overlaid on the gradient,
and equilibrium was reached by ultracentrifugation for 16 h at
33000 rpm (135000× g) in an SW41Ti rotor at 4 °C in a
Beckman Coulter optima L-90K preparative ultracentrifuge.
Gradient fractions (13 × 600 μL) were collected from the top
and the density of the fractions was determined by measuring
the mass of 100-μL aliquots of each sample.
SILAC Labeling of Human Cultured Hepatocytes
RepBlast and Huh7 cells were grown respectively in SILAC
“light” (L-arginine and L-lysine) and “heavy” (L-13C6
15N4-
arginine and L-13C6- lysine) conditions for 8 passages before
the experiment. This period lasted about 3 weeks. Cells were
lysed in hypotonic buffer (0.05% Nonidet P-40, 10 mM
HEPES/KOH pH 7.9, 1.5 mM MgCl2, 150 mM NaCl, 10 mM
KCl, 1 mM sodium orthavanadate, 5 mM NaF, 0.5 mM DTT
and protease inhibitors) at four degrees with rotation for 30
min. The lysates were cold centrifuged with 17000× g for 15
min to pellet nuclei and cellular debris. Supernatants (PNCE)
were collected, and the Bradford method was used to
determine the protein concentrations. Equal amounts (400
μg/750 μL) of the proteins from the Huh7 and RepBlast
samples were mixed and analyzed by membrane floatation and
nanoLC−MALDI. Two independent biological and technical
replicates were performed.
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Western Blotting Assay
Proteins were separated on Tris-Acetate 3−8% and Bis-Tris 4−
12% gradient polyacrylamide gels (Invitrogen) and transferred
to a nitrocellulose membrane. Membranes were then blocked
with 0.5% Tween-PBS containing 5% nonfat dried milk and
incubated overnight with the primary antibodies followed by
incubation with HRP-conjugated species-specific secondary
antibodies and enhanced chemiluminescence reaction using
ECL Plus Western Blotting Detection System.
Protein Digestion, Peptide Purification and nanoLC
Analysis
Membrane floatation-derived fractions 7, 8, and 9 obtained
from the SILAC experiment were pooled and 100 μg of
proteins were separated on 4−12% gradient gels (Invitrogen),
stained by Sypro Ruby staining and visualized using a Typhoon
9200 laser scanner (GE Healthcare). Fourteen sections of the
gel lane were cut. Protein-containing gel pieces were washed
with 100 μL of 0.1 M ammonium bicarbonate (5 min at RT).
Then, 100 μL of 100% acetonitrile (ACN) was added to each
tube and incubated for 5 min at RT. The liquid was discarded,
the washing step repeated once more, and the gel plugs were
shrunk by adding ACN. The dried gel pieces were reconstituted
with 100 μL of 10 mM DTT/0.1 M ammonium bicarbonate
and incubated for 40 min at 56 °C for cysteine reduction. The
excess liquid was then discarded and cysteines were alkylated
with 100 μL of 55 mM IAA/0.1 M ammonium bicarbonate (20
min at RT, in the dark). The liquid was discarded, the washing
step was repeated once more, and the gel plugs were shrunk by
adding ACN. The dried gel pieces were reconstituted with 12.5
ng/μL trypsin in 50 mM ammonium bicarbonate and digested
overnight at 37 °C. The supernatant from the digestion was
saved in a fresh tube and 100 μL of 1% TFA/30% ACN were
added on the gel pieces for an additional extraction of peptides.
The extracted solution and digested mixture were then
combined and vacuum centrifuged for organic component
evaporation. Peptides were resuspended with 40 μL of 2.5%
ACN/0.1% TFA, desalted and filtered through a C18
microcolumn ZipTip, and eluted from the C18 bed using
10 μL of 80% ACN/0.1% TFA. The organic component was
once again removed by evaporation in a vacuum centrifuge and
peptides were resuspended in a suitable nanoLC injection
volume (typically 3−10 μL) of 2.5% ACN/0.1% TFA. An
UltiMate 3000 nano-LC system (Dionex, Sunnyvale, CA)
equipped with an integrated nanoflow manager and micro-
vacuum degasser was used for peptide separation. The peptides
were loaded onto a 75 μm I.D. NanoSeries C18 column
(Dionex, P/N 160321) for multistep gradient elution (eluent A
0.05% TFA; eluent B 0.04% TFA in 80% ACN) from 5 to 20%
eluent B within 10 min, from 20 to 50% eluent B within 45 min
and for further 5 min from 50 to 90% eluent B with a constant
flow of 0.3 μL/min. After 5 min, the eluted sample fractions
were continuously diluted with 0.5 μL/min a-cyano-
4-hydroxycinnamic acid (CHCA) and spotted onto a MALDI
target using a Probot (LC-Packings/Dionex) with an interval of
20 s resulting in 144 fractions for each gel slice.
Mass Spectrometry Analysis
MALDI-TOF-MS spectra were acquired using a 4800 Plus
MALDI TOF/TOF Analyzer (AB Sciex, Foster City, CA). The
spectra were acquired in the positive reflector mode by 20
subspectral accumulations (each consisting of 50 laser shots) in
an 800−4000 mass range, focus mass 2100 Da, using a 355 nm
Nb:YAG laser with a 20 kV acceleration voltage. Peak labeling
was automatically done by 4000 Series Explorer software
Version 3.0 (AB Sciex) without any kind of smoothing of peaks
or baseline, considering only peaks that exceeded a signal-to-
noise ratio of 10 (local noise window 200 m/z) and a half
maximal width of 2.9 bins. Calibration was performed using
default calibration originated by five standard spots (ABI4700
Calibration Mixture). Only MS/MS spectra of preselected
peaks (out of peak pairs with a mass difference of 6.02, 10.01,
12.04, 16.03, and 20.02 Da) were integrated over 1000 laser
shots in the 1 kV positive ion mode with the metastable
suppressor turned on. Air at the medium gas pressure setting
(1.25 × 10−6 Torr) was used as the collision gas in the CID off
mode. After smoothing and baseline subtractions, spectra were
generated automatically by 4000 Series Explorer software. MS
and MS/MS spectra were processed by ProteinPilot Software
2.0.1 (AB SCIEX) which acts as an interface between the
Oracle database containing raw spectra and a local copy of the
MASCOT search engine (Version 2.1, Matrix Science, Ltd.).
The Paragon algorithm was used with SILAC (Lys+6, Arg+10)
selected as the Sample Type, iodacetamide as cysteine
alkylation, with the search option “biological modifications”
checked, and trypsin as the selected enzyme. MS/MS protein
identification was performed against the Swiss-Prot database
(number of protein sequences: 254757; released on 20070123)
without taxon restriction using a confidence threshold of 95%
(Proteinpilot Unused score ≥1.31). The monoisotopic
precursor ion tolerance was set to 0.12 Da and the MS/MS
ion tolerance to 0.3 Da. The minimum required peptide length
was set to 6 amino acids; two peptides were required for
protein identification.
For quantitation, the Heavy/Light average ratio for a protein
was calculated by ProteinPilot Software with automatic bias
correction. Quantitation was based on a two-dimensional
centroid of the isotope clusters within each SILAC pair. Ratios
of the corresponding isotope forms in the SILAC pair were
calculated, and lines fitting these intensity ratios gave the slope
as the desired peptide ratio. To represent the ratio of a peptide
being quantified several times, the median value was chosen. To
minimize the effect of outliers, protein ratios were calculated as
the median of all SILAC pair ratios that belonged to peptides
contained in this protein. The percentage of quantitation
variability was defined as the standard deviation of the natural
logarithm of all ratios used for obtaining the protein ratio
multiplied by a constant factor of 100.
Only relative Heavy/Light (or Light/Heavy) ratios exceeding
factor 1.5 were considered. Relative protein and peptides
information and raw mass spectra were exported to an Excel file
(Supplemental data 2, Supporting Information).
Data Analysis
Data were analyzed using Ingenuity Pathways Analysis. A data
set containing gene identifiers and corresponding expression
values from proteomics analysis was uploaded into the
application. Each identifier was mapped to its corresponding
object in the Ingenuity Knowledge Base. A Heavy/Light ratio
cutoff point of 1.5 was set to identify molecules whose
expression was significantly differentially regulated. These
molecules, called Network Eligible molecules, were overlaid
onto a global molecular network developed from information
contained in the Ingenuity Knowledge Base. Networks of
Network Eligible Molecules were then algorithmically
generated based on their connectivity. The Functional Analysis
of a network identified the biological functions and/or diseases
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that were most significant to the molecules in the network. The
network molecules associated with biological functions and/or
diseases in the Ingenuity Knowledge Base were considered for
the analysis. Right-tailed Fisher’s exact test was used to calculate
a p-value determining the probability that each biological
function and/or disease assigned to that network is due to
chance alone. A network is a graphical representation of the
molecular relationships between molecules. Molecules are
represented as nodes, and the biological relationship between
two nodes is represented as an edge (line). All edges are
supported by at least 1 reference from the literature, a textbook,
or from canonical information stored in the Ingenuity Pathways
Knowledge Base. Human, mouse, and rat orthologs of a gene
are stored as separate objects in the Ingenuity Pathways
Knowledge Base, but are represented as a single node in the
network. The intensity of the node color indicates the degree of
up- (green) or down- (red) regulation. Nodes are displayed
using various shapes that represent the functional class of the
gene product. Edges are displayed with various labels that
describe the nature of the relationship between the nodes.
ApoB-100 Secretion in Human Cultured Hepatocytes
Protein secretion from cultured hepatocytes was performed in a
serum-free medium for 16 h. The medium was then removed,
centrifuged (17000× g, 4 °C, 10 min) to remove cells and
debris, and secreted proteins were concentrated into ultra-
filtration columns. Samples were then dissolved in an SDS-
loading buffer and analyzed for apoB-100 by Western blotting.
ApoB-100 and Ferritin Levels in Human Plasma Samples
Plasma ferritin and apoB-100 concentrations were assessed in a
centralized laboratory using automated laboratory methods.
Production of Recombinant Retroviruses
To produce recombinant replication-incompetent retroviruses,
293GP packaging cells were transiently transfected according to
standard procedures with a pLPCX retroviral construct (BD
Biosciences, San Jose, CA) encoding HCV NS5a (genotype 1b)
or the control beta-Galactosidase protein, in the presence of a
plasmid-encoding VSV envelope protein. Culture supernatants
were collected at 48 h after transfection, filtered at 0.45 mm,
concentrated by ultracentrifugation and frozen.
RNA Extraction, Reverse Transcription and Quantitative
Real-time PCR
Total RNA was extracted by TRIzol and 1 μg was reverse
transcribed with MMLV-reverse-transcriptase (Promega, Mad-
ison, WI). Quantitative real time PCR was performed on 1:10
cDNA dilution using BioRad Miniopticon with KAPA SYBR
Green FAST qPCR mix (KAPABIOSYSTEMS, Woburn, MA).
Cycling parameters were: 95 °C for 3 min, followed by 40
cycles of 95 °C for 10s, 59 °C for 30s, 72 °C for 10s. The
relative amount of Fth mRNA was obtained by 2−ΔΔCt method
and normalized to human L34 gene expression. The following
primers were designed with PerIPrimer software: L34 sense
5′-GTCCCGAACCCCTGGTAATAG-3′; L34 antisense 5′-G-
GCCCTGCTGACATGTTTCTT-3′; Fth sense 5′-TACTGG-
AACTGCACAAACTG-3′; Fth antisense 5′-GCTTTCATTAT-
CACTGTCTCCC-3′; Ftl sense 5′-GCTACGAGCGTCTCCT-
GAAG-3′; and Ftl antisense 5′-ATGGCGTCTGGGGTTT-
TAC-3′. Data represents the mean of triplicate experiments and
statistical analysis was based on Student’s t test. HCV RNA
copy number quantification on JFH-1-infected cells were
determined as described by Mancone et al.14
siRNA Transfections and NS5a Infections
Ds-siRNA Fth-specific (sense: 5′-GAAUCAGUCACUACUGG-
AACdTdT-3′; antisense: 5′-GUUCCAGUAGUGACUGAUUC-
dTdT-3′) and ds-siRNA Ftl-specific (sense: 5′-GUCAGAAUU-
AUUCCACCGAC-3′; antisense 5′-GUCGGUGGAAUAAUUC-
UGAC-3′). The Mission Universal Negative Control siRNA was
purchased from Sigma-Aldrich (St. Louis, MO). For ds-siRNA
transfection, 4.5 × 105 RepBlast cells were plated in 60 mm
dishes and transfected with 400 pmoles of Fth-specific or
negative control ds-siRNA by Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA) following the manufacturer’s
instructions. The day after transfection, cells were washed
twice with PBS and cultured in DMEM F12 medium without
serum for 16 h. Cell-conditioned medium was then collected at
48 h after ds-siRNA transfection, and concentrated as described
previously. Cells were lysed on ice with RIPA lysis buffer
(50 mM Tris HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 5 mM
EGTA, 1% Nonidet NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) containing freshly added protease
inhibitors and 1 mM PMSF. Lysates were clarified by
centrifugation at 13000 rpm for 15 min at 4 °C and protein
concentrations were determined by Bradford assay using BSA as
a standard.
In experiments where Fth knock-down was followed by
NS5a retroviral infection, 1.5 × 105 Huh-7 cells were plated in
35 mm dishes and transfected with 200 pmoles of Fth-specific
or negative control ds-siRNA. Cell culture medium was
changed six hours after transfection and an overnight infection
was performed with NS5a and the control beta-Galactosidase
retroviral supernatants, respectively, in the presence of 4 μg/mL
Polybrene. The day after transfection, cells were washed twice with
PBS and cultured in DMEM F12 without serum for 3 h. Cell-
conditioned medium and total lysates were collected and analyzed
at 48 h after transfection.
Analysis of ROS concentration was performed on Huh7
infected with a retroviral vector expressing NS5A and treated with
Fth-specific or negative control ds-siRNA by 5−6-chloromethyl-
2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) assay
according to the manufacturer’s instructions. Cells were incubated
with CM-H2DCFDA (10 μM) for 20 min at 37 °C in the dark,
washed in cold PBS and subjected to cytofluorimetric analysis by
FACSCalibur (BD Biosciences, CA).
Immunofluorescent Microscopy
For immunofluorescence analysis, cells were fixed with 4%
paraformaldehyde, permeabilized with 0.2% Triton, blocked
with 10% donkey serum and then incubated with an anti-
CORE antibody (Anogen) for 1 h. After being washed, cells
were incubated with CyTM2-conjugated AffiniPure F(ab′)2
fragment donkey antimouse IgG secondary antibody (Immu-
noResearch Laboratories, Inc.) for 30 min. Cells were
counterstained with DAPI to label nuclei.
■ RESULTS
HCV Nonstructural Proteins Modulate the Composition of
apoB-100 Containing Subcellular Fractions
The development of selectable subgenomic HCV RNA
replicons has led to important advances in the study of the
relationship between HCV and the host lipoprotein metabo-
lism.12,14 In this study, we made use of RepBlast, a HCV
subgenomic (genotype 1b) replicon cell line derived from a
mixed population of Huh7 cells that allow for minimizing
clone-specific effects.14 First, we assessed if HCV NS expression
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affects the apoB-100 production of RepBlast cells. As expected,
the intracellular and secreted apoB-100 levels were found to be
decreased when compared with counterpart replicon-free cells
(Huh7) (Figure 1A).
To identify possible cellular effectors responsible for the
HCV-mediated inhibition of apoB-100 production, we
endeavored to make an unbiased characterization of apoB-100
containing subcellular fractions. This required investigating the
multistep process spanning from apoB-100 synthesis to
secretion. RepBlast and Huh7 cells subcellular fractions were
initially isolated from postnuclear cell extracts (PNCE) by
membrane floatation. The obtained fractions were then
analyzed for the distribution of apoB-100 by Western blotting
(Figure 1B). ApoB-100 was detected in density fractions
ranging from 1.12 to 1.16 g/mL (i.e.: fractions 7−9), as
expected from the predicted membrane-associated biogenesis
of VLDL (Figure 1B and Supplemental data 1, Supporting
Information).
Currently, several strategies for differential proteomics that
involve stable isotopes or label-free comparisons are available,
each having specific strengths and limitations. To characterize
differences in apoB-100 containing fractions between RepBlast
and Huh7 cells, we chose the SILAC proteomic approach that
allows for mixing samples before floatation assay, thus
circumventing sample differences due to the generation of
distinct density gradients (Figure 2). To this end, we
metabolically labeled Huh7 cells with 13C6
15N4-arginine and
13C6-lysine (Heavy) while RepBlast cells were grown in light
medium. PNCE were then isolated separately and equal
amounts of protein from each cell line were mixed. After
membrane flotation, apoB-100 containing fractions (7−9) were
pooled, separated by SDS-PAGE and the gel lane was cut into
14 sections ranging from 15 to 250 kDa. Proteins in each gel
section were digested and submitted to nanoLC−MALDI−
TOF/TOF analysis. We considered proteins differentially expressed
when the SILAC ratio was Heavy/Light or Light/Heavy ≥1.5 and
at least two peptides were found fragmented by MS/MS in two
independent biological replicates.
Figure 1. Characterization of apoB-100-containing vesicles. (A) Cellular and secreted apoB-100 Western blot analysis in the indicated cell lines.
NS5A was used as control for HCV-replicon expression; GAPDH and albumin for protein loading control. (B) Western blot analysis for apoB-100
intracellular distribution. Equal volumes of membrane floatation-derived vesicles isolated from both Huh7 and RepBlast cells were analyzed for
membrane (MTP, Calnexin and Golgin-97) and lumenal (MTP, Erp57 and Calreticulin) markers. The viral protein NS5A was used as control for
HCV-replicon intracellular distribution.
Figure 2. Schematic representation of SILAC-based proteomic
approach on membrane floatation-derived apoB-100 positive fractions.
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By these criteria, we found a total of 23 proteins (∼6% of the
total proteins identified) (Table 1), where 16 were over-
abundant and 7 were at lower levels in the HCV-replicon
harboring cells than in the control cells. Among them, the
following 14 were already known to be involved in biological
processes perturbed by HCV infection: ACOX3, NSDHL,
APOB, ECHS1 (lipid metabolism), TUBA1B, TUBA1C,
DPYSL2, EPPK1 (cytoskeleton remodeling), PSAT1, CANX,
GOT2, HSPA9 (protein synthesis and folding), FTL and
FTH1 (iron metabolism).15
Interaction Network Generated by Proteomic Data
Highlights Involvement of Ferritin Heavy Chain in
HCV-induced Dysregulation of apoB-100 Secretion
To infer up-regulated proteins in terms of interaction networks
or predominant canonical pathways, the differentially regulated
proteins identified in this analysis were further investigated
in silico by Ingenuity Pathway Analysis (IPA) (Ingenuity Systems,
Mountain View, CA; http://www.ingenuity.com). This allowed
for generating two networks with associated IPA scores of
45 and 9, respectively (Supporting Information Table 1). We
concentrated on data suggesting possible functional significance
in the framework of apoB-100-containing lipoprotein produc-
tion. In particular, network 1 (IPA score 45) highlights that
apoB-100 is capable of three physical interactions with
proteins found up-regulated in the RepBlast subcellular
fractions: calnexin, ferritin light chain (Ftl) and ferritin heavy
chain (Fth) (Figure 3A).16,17 In particular, the interaction
between apoB-100 and Fth (arrow in figure) is based on
literature data showing that the induction of Fth expression
results in severe inhibition of apoB-100 secretion from
hepatoma cells.18 Therefore, the combination of our
proteomic data with the literature proposes Fth as the
cellular determinant for HCV-induced inhibition of apoB-
100 production (Figure 3B). We therefore exploited this
hypothesis.
HCV-induced Fth Up-regulation Blocks apoB-100 Secretion
and Determines its Degradation via Proteasome
First, we confirmed that HCV replicon induces Fth up-
regulation by Western blot analysis. Fth was found to be up-
regulated in apoB-100 containing fractions derived from
RepBlast cells (Figure 4A). Next, to challenge the causal
correlation between viral proteins and cellular Fth up-
regulation, we induced replicon clearance by prolonged
treatment with interferon alpha (IFNα). As shown in Figure
4B, IFNα-treated RepBlast cells showed cellular Fth and apoB-
100 levels comparable with the control cells. Evidence of the
direct influence of Fth expression on the HCV-induced
dysregulation of apoB-100 production was achieved by Fth-
specific siRNA. As shown in Figure 4C, we found that the Fth
down-regulation induced increased intracellular and secreted
amounts of apoB-100, in spite of the HCV nonstructural
protein expression. Notably, the same analysis carried out on
ferritin light chain-silenced RepBlast cells did not highlight
effects on apoB-100 (Figure 4D), thus indicating that Fth plays
a specific role in apoB-100 production in these hepatoma cell
lines.
We then investigated the mechanism that leads to the Fth-
mediated inhibition of apoB-100 secretion. As mentioned,
control of apoB-100 biogenesis occurs by both co- and post-
translational mechanisms. It has been previously demonstrated
Table 1. HCV-Induced Protein Modulations in apoB-100-Containing Fractions (7−9) Identified by nanoLiquid
Chromatography−Mass Spectrometry/Mass Spectrometry
acc. numbera gene namea protein name SILAC average ratio ± SDb protein scorec seq. coverage % number of peptides
HCV-replicon up-regulated proteins (Light/Heavy)
P01023 A2M Alpha-2-macroglobulin 6.62 ± 4.79 5.15 9.2 13
P38646 HSPA9 Stress-70 protein, mitochondrial 4.79 ± 4.11 13.34 26.2 18
Q9BSE5 AGMAT Agmatinase, mitochondrial 4.66 ± 3.51 4.00 8.5 3
P00505 GOT2 Aspartate aminotransferase, mitochondrial 4.00 ± 3.18 8.32 17.9 8
Q9BPW8 NIPSNAP1 Protein NipSnap1 homologue 1 3.62 ± 2.73 6.11 23.9 6
P30084 ECHS1 Enoyl-CoA hydratase, mitochondrial 3.45 ± 2.20 7.64 56.6 16
Q15738 NSDHL Sterol-4-alpha-carboxylate 3-dehydrogenase 2.63 ± 1.51 4.10 11.0 3
P58107 EPPK1 Epiplakin 2.42 ± 1.29 22.85 40.3 71
P02792 FTL Ferritin light chain 2.32 ± 1.29 11.56 68.6 14
P27824 CANX Calnexin 2.21 ± 0.69 5.32 14.2 9
P05091 ALDH2 Aldehyde dehydrogenase, mitochondrial 2.11 ± 0.09 8.00 22.2 8
P02794 FTH1 Ferritin heavy chain 2.02 ± 0.68 11.49 57.4 11
Q16881 TXNRD1 Thioredoxin reductase 1, cytoplasmic 1.63 ± 0.42 9.60 44.9 19
Q04828 AKR1C1 Aldo-keto reductase family 1 member C1 1.56 ± 0.00 16.89 63.2 15
P16279 GLB1 Beta-galactosidase 1.53 ± 0.20 5.22 20.9 12
O15254 ACOX3 Peroxisomal acyl-coenzyme A oxidase 3 1.50 ± 0.01 4.00 17.4 10
HCV-replicon down-regulated proteins (Heavy/Light)
P12277 CKB Creatine kinase B-type 1.90 ± 0.39 26.27 66.4 19
Q01581 HMGCS1 Hydroxymethylglutaryl-CoA synthase 1.86 ± 0.23 14.01 32.3 14
Q16555 DPYSL2 Dihydropyrimidinase-related protein 2 1.60 ± 0.10 17.35 46.0 23
Q9Y617 PSAT1 Phosphoserine aminotransferase 1.57 ± 0.27 13.98 29.7 9
P04114 APOB Apolipoprotein B-100 1.52 ± 0.02 16.11 19.2 83
P68363 TUBA1B Tubulin alpha-1B chain 1.52 ± 0.27 34.05 55.4 19
Q9BQE3 TUBA1C Tubulin alpha-1C chain 1.51 ± 0.33 5.35 24.5 8
aAccording to the UniProtKB/Swiss-Prot entry. bAverage protein ratios (Heavy/Light and Light/Heavy) and standard deviations (SD) were
determined by the mean of two independent biological analyses. For details, see Experimental Section. cProteinPilot Unused ProtScore (Conf) >1.30
(95.0%).
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that Fth inhibits apoB-100 ER export leading to its increased
proteasome-associated degradation.18 Therefore, we tested if the
HCV-induced Fth up-regulation affects apoB-100 production with
the same post-transcriptional mechanism. To this end, we treated
Huh7 and RepBlast cell lines with MG-132, a specific inhibitor of
proteasome. The intracellular and secreted amounts of apoB-100
were analyzed by Western blotting. When treated with MG-132,
RepBlast cells show similar amounts of apoB-100 as control Huh7,
while its secretion is inhibited (Figure 4E), thus indicating that
apoB-100 increased proteasome degradation is a secondary event
that follows inhibition of secretion.
Taken together, these results demonstrate that HCV inhibits
apoB-100 production by Fth-mediated post-translational block
in secretion.
HCV Nonstructural Protein Expression Induces Fth
Up-regulation Independent of Iron-induced and Oxidative
Stress-based Mechanisms
Next, we aimed to gain insight on the molecular mechanism by
which HCV NS proteins induce Fth expression. It is well-
known that Fth synthesis is regulated at a transcriptional level
in response to oxidative stress and post-transcriptionally by
cytosolic iron.19,20 Using RT-qPCR analysis, we found that
RepBlast cells expressed statistically significantly higher levels of
Fth mRNA in respect to Huh7 (Figure 5A). Notably, the
clearance of HCV replicon abolished this difference, thus
demonstrating that HCV induces Fth up-regulation at a
transcriptional level.
To assess whether HCV NS proteins-induced Fth up-regulation
is mediated by oxidative stress, we measured Fth mRNA levels
in response to the antioxidant N-acetyl cysteine (NAC). As
expected, HCV replicon expression increased ROS production
(Figure 5B). Interestingly, NAC treatment, while lowering ROS
production, did not influence HCV-induced Fth up-regulation
(Figure 5B and C). Similar results were obtained by using
L-ascorbic acid as an antioxidant (data not shown). These
results demonstrate that HCV replicon expression leads to Fth
transcriptional activation independent of cellular oxidative
stress status.
Figure 3. Protein network generation on the apoB-100 structural and functional interactions. (A) SILAC data obtained by comparing the apoB-100
positive fractions of Huh7 and RepBlast cells were analyzed by IPA. HCV-induced protein modulations are indicated in green (up-regulated) and red
(down-regulated); arrows denote functional relationships. Symbols are indicated in the legend. (B) Schematic representation of Fth as the cellular
determinant of the HCV-induced apoB-100 production inhibition.
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Viral Protein NS5A Is Sufficient to Up-regulate Ferritin
Heavy Chain Expression
NS5A protein was found to physically interact with Fth.21 To
investigate the role of NS5A in the Fth-mediated inhibition of
apoB-100 production, we generated Huh7 cells that only
expressed this viral protein. As shown in Figure 6A, NS5A was
found to be sufficient in inducing Fth up-regulation and
decreasing intracellular and secreted apoB-100 levels. More-
over, similar to HCV-replicon harboring cells, the siRNA-
mediated down-regulation of Fth protein induced increased
intracellular and secreted amounts of apoB-100 in Huh7 cells
expressing NS5A alone (Figure 6B).
Taken together, these results demonstrate that the viral
protein NS5A is sufficient to induce the synthesis of Fth, which
acts as determinant for HCV-induced inhibition of apoB-100
production.
Fth Is Required for Robust HCV Infections
Next, we aimed at extending our observations to the JFH-1
HCVcc (genotype 2a) natural infection system which generates
infectious HCV particles in the Huh7−5.1 hepatoma cell line,
Figure 4. HCV-mediated inhibition of apoB-100 secretion occurs by Fth up-regulation. (A) Fth and apoB-100 Western blot analysis of membrane
floatation-derived vesicles in the indicated cell lines. (B) Fth and apoB-100 Western blot analysis of total protein extracts isolated from the indicated
cell lines in the presence or absence of IFNα. (C) Cellular and secreted Western blot analysis for the indicated proteins in RepBlast cells transfected
either with Fth specific or control siRNA. (D) Cellular and secreted Western blot analysis for the indicated proteins in RepBlast cells transfected
either with Ftl specific or control siRNA. (E) Fth and apoB-100 Western blot analysis in total protein extracts and secreted proteins obtained from
the indicated cell lines in the presence or absence of MG-132. NS5A was used as control for HCV-replicon expression for all the analyses; GAPDH
and albumin for protein loading control.
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thus recapitulating the complete viral life cycle.22 To this end,
naıv̈e Huh7.5.1 cells were HCV-infected and at 4 days
postinfection, both the apoB-100 production and the Fth
expression were measured by Western blotting analysis. As
shown in Figure 7A, Fth expression in HCV-infected cells
(JFH-1) was found to be up-regulated while the intracellular
and secreted apoB-100 levels were affected. Since HCV
production is dependent on assembly and secretion of very
low-density lipoproteins13 we assessed whether Fth down-
regulation, restoring high levels of apoB-100 production, may
boost viral production. To this aim, Huh7−5.1 cells were
transfected with either Fth-specific siRNA or control siRNA and,
after 24 h, infected with HCV (MOI = 0.1) for 2 h. The effect of
Fth siRNA on HCV production was assessed by quantifying the
viral RNA released in the medium 4 days postinfection.
Surprisingly, while apoB-100 cellular and secreted levels were
found to be increased, Fth specific down-regulation considerably
reduced the viral RNA in the medium (Figure 7D). These data
indicate that Fth up-regulation is required for efficient viral
infection as underscored by the inverse correlation found between
the intracellular amounts of HCV core protein and Fth expression
(Figure 7B and C).
Figure 5. HCV replicon expression transcriptionally activates Fth independent of oxidative stress. (A) Fth RT-qPCR analysis in the indicated cell
lines in the presence or absence of IFNα. (B) CM-H2DCFDA (5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester)-
induced fluorescence flow cytometry assay and (C) Fth RT-qPCR analysis in the indicated cell lines in the presence or absence of N-acetyl cysteine
(NAC) (10 μM for 4 h). Data represent means ± SD from biological triplicates.
Figure 6. NS5A alone recapitulates the HCV-induced inhibition of apoB-100 secretion. (A) Cellular and secreted Western blot analysis for the
indicated proteins in the presence or absence of NS5A. Huh7 cells were infected with NS5A or β-gal expressing vectors. (B) Cellular and secreted
Western blot analysis for the indicated proteins in NS5A-infected Huh7 cells transfected either with Fth specific or control siRNA. GAPDH and
albumin were used for protein loading control.
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Inverse Correlation between Fth Expression and apoB-100
Production in HCV-infected Patients
Finally, we verified the robustness of the inverse association be-
tween Fth expression and apoB-100 secretion in HCV-infected
patients. Hepatic iron accumulation has been shown to be
present mainly in male patients with chronic hepatitis C.23
However, it remains unknown whether high liver ferritin
concentration could be related to apoB-100 dysregulation.
Figure 7. ApoB-100 secretion inversely correlates with ferritin concentration in HCV-infected cells and patients. (A) Cellular and secreted Western blot analysis
for the indicated proteins in parental (Huh7−5.1) and JFH-1-infected cells. Core was used as control for HCV infection; GAPDH and albumin for protein
loading control. (B) Cellular and secreted Western blot analysis for the indicated proteins in JFH-1-infected cells transfected either with Fth specific or control
siRNA. Cells were transfected 24 h before infection and lysed 4 days postinfection. (C) Immunofluorescence analysis for core expression in JFH-1-infected cells
transfected either with Fth specific or control siRNA 24 h before infection. Cells were transfected 24 h before infection, fixed 4 days postinfection and subjected
to immunofluorescence microscopy as described in the Experimental section. The histogram in the box indicates the percentage of core positive cells (means ±
SD; p < 0.0005) obtained from counts of 7 different random fields. (D) RT-qPCR analysis of HCV RNA copy number present in the culture medium of Fth
specific or control siRNA-treated cells 4 days after infection. Data represent means ± SD from biological triplicates. (E) Analysis of circulating apoB-100 levels in
HCV-infected patients with normal (≤400 ng/mL) and high (>400 ng/mL) plasma ferritin concentrations. Changes in circulating apoB-100 levels are
represented as box plots. The number of patients (n) is indicated in the horizontal axes. For details and statistical analysis, see Supporting Information Table 2.
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We addressed this issue analyzing the relationship between
HCV infection, circulating apoB-100 levels and plasma ferritin
concentration; the latter is in fact known to reflect the level of
ferritin chain expression in the liver.24 As expected, high ferritin
concentration (>400 ng/mL) (found exclusively in male donors)
represented 40% of the HCV-infected patients (Figure 7E and
Supporting Information Table 2). Interestingly, we found the
mean value of apoB-100 concentration in patients with high
ferritin levels to be significantly lower (70 ± 23 mg/dL, p =
0.018) than what was observed in the group with normal ferritin
levels (86 ± 27 mg/dL), thus confirming the inverse association
between Fth expression and the levels of apoB-100 secretion.
Comparable results were obtained considering only the male
population in the low ferritin group (Supporting Information
Table 3).
Altogether, our results demonstrate that Fth up-regulation is
the mechanism by which HCV affects apoB-100 production.
■ DISCUSSION
Here we have demonstrated that HCV infection up-regulates
Fth expression which in turn specifically affects the production
of apoB-100-containing lipoprotein particles. Our contribution
originated from proteomic analysis and a literature oriented
hypothesis. In fact, two elegant reports demonstrated the
influences of: (i) HCV on hepatic iron accumulation25 and
(ii) Fth up-regulation on apoB-100 secretion.18 We linked these
observations to new in vivo and in vitro findings.
Specifically, Nishina and colleagues demonstrated that in
transgenic mice, the HCV-induced down-regulation of hepatic
hepcidin leads to hepatic iron overloading and consequently, to
ferritin up-regulation.25 Here, we show that HCV-induced Fth
up-regulation also occurs at a transcriptional level, independent
of an oxidative stress-based mechanism.
Hevi and Chuck clarified the intersection between the
pathways for iron storage and apoB-100 production: Fth was
described as apoB-100 binding protein, inhibiting its
secretion.18 Here, we show that the viral protein NS5A alone
can sufficiently increase Fth expression leading to reduced
levels of apoB-100 secretion.
Although HCV and apoB-100-containing lipoprotein assem-
bly machineries share the same cellular compartments26 and
NS5A physically interacts with apoB-100,12 our finding
excludes the hypothesis that the viral protein has an exclusive
role in blocking exportation of apoB-100. In fact, a specific
down-regulation of Fth by siRNA restores high levels of
apoB-100 production, even in the presence of NS5A.
In search of the molecular mechanism causing HCV-induced
Fth-mediated inhibition of apoB-100 production, we high-
lighted that HCV-induced Fth expression blocks apoB-100
secretion, leading to increased degradation via proteasomes. In
light of this, the apoB-100 intracellular decreased levels are not
the result of a general apoB-100 synthesis down-regulation but
rather the result of post-translational degradation. So far, the
paucity of available informations on VLDL biogenesis, renders
investigation of the molecular platform blocking ER apoB-100
export difficult; further investigations on ER-associated vesicle
packaging and release of apoB-100 are needed.
The HCV-induced decrement of apoB-100-containing lip-
oprotein secretion is in contrast with the functional role of the
VLDL pathway in the assembly and secretion of infectious viral
particles.13 The observation that high levels of Fth expression
are required for efficient viral infection might explain this
paradox. In fact, in cells receiving the Fth siRNA, potential
increments of viral particle production resulting from the
increased apoB-100 secretion were nullified from a reduced
level of infection. Moreover, since Fth down-regulation do not
affect HCV replication (Figure 4C), the reduced levels of
intracellular core expression observed in HCV-infected cells
(Figure 7B and C) suggest a potential involvement of Fth in the
first steps of viral life cycle (e.g., cell attachment and entry). In
this scenario, HCV infection might benefit from the Fth
binding affinity for various molecules and several of its noniron-
mediated functions.27 Future experiments on topology and
processes involving the interactions among Fth, HCV envelope
proteins and viral cell surface receptors might unveil a possible
role of Fth in the HCV life cycle.
To our knowledge, our in vivo data are the first reports that
show the inverse correlation between plasma apoB-100 and
ferritin concentrations. The novelty of our finding is due to the
paucity of apoB-100 assays performed in the monitoring of lipid
metabolism, both in the clinical practice of HCV-infection and
in the treatment of iron-related diseases.
While supported by in vitro observations, the in vivo results
remain to be integrated and interpreted in a more general
context. Indeed, a variety of factors as hormones, chemokines,
cytokines, diet, life style, genetic factors, viral load and degree of
liver damage are known to influence serum apoB-100 and
ferritin concentrations.2,9,11,20,28
However, we believe that our results provide a new rationale
for iron depletion therapy in HCV-infected patients within the
framework of interferon-based therapy.29,30 In fact, iron
depletion, which reduces hepatic ferritin concentration and
favors lipid exportation, might be taken into account as an
additional therapeutic strategy to counteract hepatic lipid
accumulation and hepatitis C progression. Moreover, iron
accumulation is also a serious risk factor for HCC, playing a
critical role in the onset of liver steatosis31 by both increasing
lipidogenesis and reducing intracellular lipid catabolism.32,33
In conclusion, our study indicates that Fth is an important
regulator of apoB-100-containing lipoproteins production and a
host factor required for HCV infection, thus allowing to
hypothesize new therapeutic interventions.
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